BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25482372)

  • 1. Methylation status of IGFBP-3 as a useful clinical tool for deciding on a concomitant radiotherapy.
    Pernía O; Belda-Iniesta C; Pulido V; Cortes-Sempere M; Rodriguez C; Vera O; Soto J; Jiménez J; Taus A; Rojo F; Arriola E; Rovira A; Albanell J; Macías MT; de Castro J; Perona R; Ibañez de Caceres I
    Epigenetics; 2014 Nov; 9(11):1446-53. PubMed ID: 25482372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
    Cortés-Sempere M; de Miguel MP; Pernía O; Rodriguez C; de Castro Carpeño J; Nistal M; Conde E; López-Ríos F; Belda-Iniesta C; Perona R; Ibanez de Caceres I
    Oncogene; 2013 Mar; 32(10):1274-83. PubMed ID: 22543588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
    Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer.
    Chang YS; Wang L; Liu D; Mao L; Hong WK; Khuri FR; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3669-75. PubMed ID: 12473575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
    Wu F; Lu M; Qu L; Li DQ; Hu CH
    Int J Clin Exp Pathol; 2015; 8(5):5457-63. PubMed ID: 26191250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter methylation-mediated silencing of β-catenin enhances invasiveness of non-small cell lung cancer and predicts adverse prognosis.
    Miao Y; Wang L; Zhang X; Xu X; Jiang G; Fan C; Liu Y; Lin X; Yu J; Zhang Y; Wang E
    PLoS One; 2014; 9(11):e112258. PubMed ID: 25396757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer.
    Chang YS; Wang L; Suh YA; Mao L; Karpen SJ; Khuri FR; Hong WK; Lee HY
    Oncogene; 2004 Aug; 23(39):6569-80. PubMed ID: 15247904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
    Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
    Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.
    Sonett JR; Suntharalingam M; Edelman MJ; Patel AB; Gamliel Z; Doyle A; Hausner P; Krasna M
    Ann Thorac Surg; 2004 Oct; 78(4):1200-5; discussion 1206. PubMed ID: 15464470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.
    Kim YH; Sumiyoshi S; Hashimoto S; Masago K; Togashi Y; Sakamori Y; Okuda C; Mio T; Mishima M
    Clin Lung Cancer; 2012 Sep; 13(5):385-90. PubMed ID: 22285568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional and posttranslational regulation of insulin-like growth factor binding protein-3 by Akt3.
    Jin Q; Lee HJ; Min HY; Smith JK; Hwang SJ; Whang YM; Kim WY; Kim YH; Lee HY
    Carcinogenesis; 2014 Oct; 35(10):2232-43. PubMed ID: 24942865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
    Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
    Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
    Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
    Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
    Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
    Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [RUNX3 promoter hypermethylation and prognosis of early surgically resected non-small cell lung cancers].
    Tang Y; Wu F; Hu C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jul; 36(7):650-4. PubMed ID: 21873791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.
    Douillard JY; Rosell R; De Lena M; Riggi M; Hurteloup P; Mahe MA;
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):695-701. PubMed ID: 18439766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
    Chang YS; Kong G; Sun S; Liu D; El-Naggar AK; Khuri FR; Hong WK; Lee HY
    Clin Cancer Res; 2002 Dec; 8(12):3796-802. PubMed ID: 12473592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.